Abstract
The development of novel adjuvants constitutes a new strategy for the research of tumor vaccines. Immunomodulatory molecule adjuvants are one of the novel adjuvants that can effectively stimulate the pattern recognition receptors to activate the downstream pathways of immune cells. However, there are few studies on immunomodulatory molecular adjuvants associated with C-type lectin. It has been reported that GlcC14C18 is a Mincle ligand with a relatively simple structure and strong adjuvant activity in vivo. Herein, we coupled GlcC14C18 with MUC1 glycopeptide and evaluated its immune effect. In addition, we also synthesized α-GlcC14C18-MUC1 and β-GlcC14C18-MUC1 based on the two configurations of GlcC14C18 and compared their immune effects. The results show that both of the two configurations of the vaccine have a good immune effect, but to a certain extent, the immune effect of β-GlcC14C18-MUC1 is better than that of α-GlcC14C18-MUC1.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
